Clinical Trials
31 trialsNovel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
PED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
GBM AGILE
Global Coalition for Adaptive Research
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
MRG003
Sun Yat-sen University
ARISTOCRAT
University of Birmingham
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
PEEL-224
Children's Hospital of Philadelphia
LUPARPED
Fundación de investigación HM
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Baylor College of Medicine
DUAL-NK-NB
Beijing Biotech
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
MEMMAT
Medical University of Vienna
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phenix
Centre Hospitalier Universitaire Vaudois
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
IA Carboplatin + Radiotherapy in Relapsing GBM
Université de Sherbrooke
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
GBrecurr
University Hospital, Bordeaux
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Kian Immune Cell Company
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Nanjing Children's Hospital
NALIRIBVRG
The Central Hospital of Lishui City
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
The General Hospital of Western Theater Command
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Beijing Sanbo Brain Hospital
Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
Asan Medical Center
RECMAP
Erasmus Medical Center
circTeloDIAG
Hospices Civils de Lyon